Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2011-001644-29
    Sponsor's Protocol Code Number:SAS115359
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2012-02-28
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2011-001644-29
    A.3Full title of the trial
    SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone Propionate/Salmeterol Combination versus Inhaled Fluticasone Propionate in the Treatment of Adolescent and Adult Subjects with Asthma.
    SAS115359, Studio sulla sicurezza e sull' efficacia della combinazione di fluticasone propionato/ e salmeterolo per via inalatoria rispetto a fluticasone propionato per via inalatoria nel trattamento di soggetti adolescenti e adulti affetti da asma
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A 6-month study to assess the safety and benefit of inhaled fluticasone propionate/salmeterol combination compared with inhaled fluticasone propionate in the treatment of adolescents (12 years and over) and adults with asthma.
    Studio di 6 mesi sulla sicurezza e sul beneficio della combinazione di fluticasone propionato/ e salmeterolo per via inalatoria rispetto a fluticasone propionato per via inalatoria nel trattamento di soggetti adolescenti (dai 12 anni in poi) e adulti con asma
    A.3.2Name or abbreviated title of the trial where available
    AUSTRI
    AUSTRI
    A.4.1Sponsor's protocol code numberSAS115359
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGLAXOSMITHKLINE RESEARCH & DEVELOPMENT LTD.
    B.5.2Functional name of contact pointGSK Clinical Support HelpDesk
    B.5.3 Address:
    B.5.3.1Street AddressIron Bridge Rd,
    B.5.3.2Town/ cityStockley Park West, Uxbridge
    B.5.3.3Post codeUB11 1BU
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number+44 0208 990 4466
    B.5.5Fax number+44 0208 990 4968
    B.5.6E-mailGSKClinicalSupportHD@gsk.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Flixotide Accuhaler 100 micrograms
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Seretide 100 Accuhaler
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSALMETEROL XINAFOATE
    D.3.9.1CAS number 94749-08-3
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB04314MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Flixotide Accuhaler 250 micrograms
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Seretide 250 Accuhaler
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSALMETEROL XINAFOATE
    D.3.9.1CAS number 94749-08-3
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB04314MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number250
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Flixotide Accuhaler 500 micrograms
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Seretide 500 Accuhaler
    D.2.1.1.2Name of the Marketing Authorisation holderGlaxo Wellcome UK Limited
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Inhalation powder
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNSALMETEROL XINAFOATE
    D.3.9.1CAS number 94749-08-3
    D.3.9.2Current sponsor codeNA
    D.3.9.3Other descriptive nameNA
    D.3.9.4EV Substance CodeSUB04314MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNFLUTICASONE PROPIONATE
    D.3.9.1CAS number 80474-14-2
    D.3.9.2Current sponsor codeNA
    D.3.9.4EV Substance CodeSUB02241MIG
    D.3.10 Strength
    D.3.10.1Concentration unit µg microgram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number500
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Asthma
    Asma
    E.1.1.1Medical condition in easily understood language
    Asthma
    Asma
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 14.1
    E.1.2Level PT
    E.1.2Classification code 10003553
    E.1.2Term Asthma
    E.1.2System Organ Class 10038738 - Respiratory, thoracic and mediastinal disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of the study is to evaluate whether the addition of LABA to ICS therapy (FSC) is non-inferior to ICS therapy alone (FP) in terms of the risk of serious asthma related events (asthma-related hospitalization, endotracheal intubation, and death).
    L’obiettivo primario dello studio è valutare se la terapia di combinazione con ICS più LABA (FSC) sia non inferiore alla monoterapia a base di ICS (FP) in termini di rischio di eventi asma-correlati gravi (ospedalizzazione, intubazione endotracheale e morte per asma).
    E.2.2Secondary objectives of the trial
    A secondary objective of the study is to evaluate whether the addition of LABA to ICS therapy (FSC) is superior to ICS therapy alone (FP) in terms of measures of efficacy.
    Un obiettivo secondario dello studio è valutare se la terapia combinata con LABA più ICS (FSC) sia superiore alla monoterapia con ICS (FP) in termini di misure di efficacia.
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    PHARMACOGENETIC:
    Vers:01
    Date:2011/09/13
    Title:SAS115359, a Safety and Efficacy Study of Inhaled Fluticasone
    Propionate/Salmeterol Combination versus Inhaled Fluticasone
    Propionate in the Treatment of Adolescent and Adult Subjects
    with Asthma - Appendix 1: Pharmacogenetics
    Objectives:The objective of the PGx research (if there is a potential unexpected or unexplained variation) is to investigate a possible genetic relationship to handling or response to FSC or FP.

    FARMACOGENETICA:
    Vers:01
    Data:2011/09/13
    Titolo:SAS115359, Studio sulla sicurezza e sull’efficacia della combinazione di fluticasone propionato/ e salmeterolo per via inalatoria rispetto a fluticasone propionato per via inalatoria nel trattamento di soggetti adolescenti e adulti affetti da asma - Appendice 1: Farmacogenetica
    Obiettivi:L'obiettivo della ricerca PGx (se c'è una variazione potenzialmente
    inattesa o inspiegabile) è di verificare una possibile relazione genetica alla gestione o risposta a FSC per via inalatoria o a FP per via inalatoria.

    E.3Principal inclusion criteria
    French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category. 1. Informed Consent: • The subject and/or the subject's legal guardian (if applicable) must provide written informed assent/consent to take part in the study. • Subjects and/or their legal guardians (if applicable) understand that they must comply with study treatment and study assessments including recording of daily information regarding their asthma status and attend scheduled study visits, and be accessible by telephone. 2. Subject: 12 years of age and older. 3. Gender: Male or female. 4. Asthma Diagnosis: Persistent asthma, defined by national and international asthma guidelines [GINA, 2009; NIH, 2007; etc.] for at least 1 year prior to study enrolment. If the subject is naïve to the study site, the diagnosis of asthma must be confirmed by subject history. 5. PEF: A clinic PEF≥50% of predicted normal value. Percent predicted PEF values must be calculated using NHANES III with relevant equations that adjust for race and national origin. [Hankinson, 1999; Hankinson, 2010]. 6. Current Asthma Therapy: Subjects must be appropriately using one of the following for the treatment of asthma and meet the criteria outlined below: • ICS or ICS with one or more adjunctive therapies (LABA, LTRA or theophylline) for at least 4 weeks prior to randomization (see Table 1: for ICS dose equivalents). Any subject maintained on a stable high dose ICS or stable high dose ICS with one or more adjunctive therapies (LABA, LTRA or theophylline) must have an ACQ-6 < 1.5 (i.e., controlled) at Visit 1. • Leukotriene receptor antagonist (i.e. LTRAs such as montelukast, zafirlukast, or pranlukast) OR theophylline as monotherapy at a stable dose for at least 4 weeks prior to randomization. Subjects on LTRAs or theophylline are eligible only if they record an ACQ-6 score of ≥ 1.5 (i.e. not well controlled) and in the Investigator's clinical judgement, the subject's asthma severity could justify treatment with ICS or ICS + LABA. • Daily rescue medication (e.g., albuterol/salbutamol or other inhaled short-acting beta-agonist used to treat acute asthma) in the 4 weeks prior to randomization. Subjects on daily rescue medication are eligible only if they record an ACQ-6 score of ≥ 1.5 and in the investigator's clinical judgement, the subject's asthma severity could justify treatment with ICS or ICS + LABA. 7. Exacerbation History: Subject must have a history of one of the following: • at least one asthma exacerbation requiring treatment with a systemic corticosteroid (tablets, suspension, or injection) between 30 days and 12 months prior to randomization OR • an asthma-related hospitalization (defined as an inpatient stay or a 24-hour stay in an observation area in an emergency room or other equivalent facility) between 30 days and 12 months prior to randomization 8. Questionnaire: Ability to answer questions regarding asthma status and quality of life and ability to use a daily electronic data capture system. 9. Inhaler Usage: Ability to demonstrate proper use of a metered-dose inhaler and dry powder inhaler (DPI) device.
    Soggetti francesi: in Francia, un soggetto sarà idoneo all’inclusione in questo studio solo se affiliato o beneficiario di un regime di previdenza sociale. 1. Consenso informato:  per prendere parte allo studio il soggetto e/o il suo tutore legale (se applicabile) devono prestare l’assenso/il consenso informato scritto;  i soggetti e/o i loro tutori legali (se applicabile) comprendono di dover osservare il trattamento in studio e le valutazioni di studio, inclusa la registrazione su base quotidiana delle informazioni relative allo stato dell’asma, di doversi presentare alle visite di studio programmate e di dover essere reperibili telefonicamente. 2. Soggetto: età ≥ 12 anni. 3. Sesso: entrambi. 4. Diagnosi di asma: asma persistente, come definita dalle linee guida nazionali e internazionali sull’asma [GINA, 2009; NIH, 2007; ecc.], da almeno 1 anno prima dell’arruolamento nello studio. Qualora il soggetto si rivolga per la prima volta al centro di studio, la diagnosi di asma deve essere confermata dall’anamnesi. 5. PEF: ≥ 50% del valore normale predetto. I valori percentuali di PEF previsti devono essere calcolati utilizzando i valori di riferimento NHANES III con le relative equazioni aggiustate per il gruppo etnico e la nazionalità. [Hankinson, 1999; Hankinson, 2010]. 6. Terapia corrente per l’asma: i soggetti devono assumere correttamente uno dei trattamenti per l’asma seguenti e soddisfare i criteri illustrati di seguito.  ICS o ICS in associazione a una o più terapie aggiuntive (LABA, antagonisti dei recettori leucotrienici [LTRA] o teofillina) da almeno 4 settimane precedenti la randomizzazione (vedere Tabella 1 per le dosi equivalenti di ICS). Tutti i soggetti che assumono una dose elevata stabile di ICS o una dose elevata stabile di ICS in associazione a una o più terapie aggiuntive (LABA, LTRA o teofillina) devono presentare un punteggio ACQ-6 &lt; 1,5 (ovvero asma controllata) alla Visita 1.  LTRA (come montelukast, zafirlukast o pranlukast) OPPURE teofillina somministrati in monoterapia a una dose stabile da almeno 4 settimane precedenti la randomizzazione. I soggetti in terapia con LTRA o teofillina sono idonei solo se presentano un punteggio ACQ-6 ≥ 1,5 (ovvero asma non adeguatamente controllata) e qualora, secondo il giudizio clinico dello Sperimentatore, la gravità della loro asma possa giustificare il trattamento con ICS o ICS + LABA.  Farmaco di emergenza ad uso giornaliero (p. es. albuterolo/salbutamolo o altro beta agonista a breve durata d’azione usato per via inalatoria per il trattamento dell’asma acuta) nelle 4 settimane precedenti la randomizzazione. I soggetti che assumono farmaci di emergenza ad uso giornaliero sono idonei solo se presentano un punteggio ACQ-6 ≥ 1,5 e qualora, secondo il giudizio clinico dello Sperimentatore, la gravità della loro asma possa giustificare il trattamento con ICS o ICS + LABA. 7. Precedenti esacerbazioni: il soggetto deve essere stato interessato da uno degli eventi seguenti:  almeno una esacerbazione dell’asma che ha richiesto il trattamento con un corticosteroide per via sistemica (compresse, sospensione o iniezione) tra 30 giorni e 12 mesi precedenti la randomizzazione OPPURE  un’ospedalizzazione dovuta all’asma (definita come ricovero o periodo di degenza di 24 ore in OBI o altra struttura equivalente) tra 30 giorni e 12 mesi precedenti la randomizzazione. 8. Questionario: capacità di rispondere a domande relative allo stato dell’asma e alla qualità di vita e di utilizzare giornalmente un sistema di acquisizione dati elettronico. 9. Uso dell’inalatore: capacità di dimostrare l’uso corretto di un dispositivo MDI (inalatore pressurizzato predosato) e DPI (inalatore a polvere secca).
    E.4Principal exclusion criteria
    1. History of Life-Threatening Asthma: Defined for this protocol as an asthma episode that required intubation and/or was associated withhypercapnea requiring non-invasive ventilatory support. 2. Concurrent Respiratory Disease: Subjects with current evidence of pneumonia, pneumothorax, atelectasis, pulmonary fibrotic disease, allergic bronchopulmonary aspergillosis, cystic fibrosis, bronchopulmonary dysplasia, or other respiratory abnormalities other than asthma. 3. Chronic Obstructive Pulmonary Disease: chronic bronchitis, emphysema, or chronic obstructive pulmonary disease. 4. Tobacco Use. 5. Exercise-induced Asthma: Subjects with exercise induced asthma (as the only asthma-related diagnosis) not requiring daily asthma control medicine. 6. Respiratory Infection: Culture-documented or suspected bacterial or viral infection of the upper or lower respiratory tract, sinus or middle ear that is not resolved at randomization. 7. Unstable Asthma Status: Subjects must not meet the following unstable asthma severity criteria within 7-days prior to randomization: • Asthma symptoms that persisted throughout the day on 2 consecutive days • Nighttime awakening due to asthma ≥3 times • Albuterol/salbutamol (or equivalent) use for the acute worsening of asthma symptoms >8 puffs a day over 2 consecutive days or ≥25 puffs in one day • Asthma symptoms so severe that the subject was limited in their ability to perform normal daily activity on any 1 day 8. Asthma Exacerbation: An asthma exacerbation requiring systemic (tablets, suspension or injection) corticosteroids within 4 weeks of randomization or more than 4 separate exacerbations in the 12 months preceding randomization. For exacerbations to be considered separate events there must be at least 7 days from the resolution of one exacerbation to the start of the second exacerbation. 9. Asthma Hospitalizations: More than 2 hospitalizations for greater than 24 hours duration for treatment of asthma in the 12 months preceding randomization. Each hospitalization must be separated by >7 days to be considered an individual event. 10. Pregnancy and Lactation: Female subjects should not be enrolled if they are pregnant, lactating or plan to become pregnant during the time of study participation. All females of childbearing potential must have a negative urine pregnancy test result prior to randomization to continue in the study. 11. Concurrent Diseases/Abnormalities: A subject with any known, preexisting, clinically significant condition, disorder or disease of any body or organ system that is uncontrolled with standard treatment and that, in the opinion of the investigator, would put the safety of the subject at risk through study participation or would confound the interpretation of the results if the condition, disorder or disease exacerbated during the study. 12. Investigational Medications: A subject who has participated in an interventional study, or used any investigational drug for any disease state, within 30 days prior to randomization. 13. Participation in a Concurrent LABA Safety Study - please refer to Protocol for the following criteria.
    1. Storia di asma potenzialmente fatale: definita, per il presente protocollo, come un episodio di asma che ha richiesto intubazione e/o associato a ipercapnia con necessità di supporto respiratorio non invasivo. 2. Malattia respiratoria concomitante: soggetti con evidenza corrente di polmonite, pneumotorace, atelectasia, fibrosi polmonare, aspergillosi broncopolmonare allergica, fibrosi cistica, displasia broncopolmonare o altre anomalie respiratorie diverse dall’asma. 3. Broncopneumopatia cronica ostruttiva: soggetti con evidenza corrente o diagnosi medica di bronchite cronica, enfisema o broncopneumopatia cronica ostruttiva. 4. Fumo: storia di fumo &gt; 10 pacchetti /anno (numero di pacchetti /anno è definito come il numero di sigarette al giorno/20 x numero di anni di fumo). 5. Asma indotta da esercizio fisico: soggetti con asma indotta da esercizio fisico (quale unica diagnosi asma-correlata) che non necessita di controllo farmacologico giornaliero. 6. Infezione delle vie respiratorie: infezione batterica o virale documentata da coltura o sospetta del tratto respiratorio superiore o inferiore, dei seni nasali o dell’orecchio medio non risolta alla randomizzazione. 7. Stato di asma instabile: i soggetti non devono soddisfare i criteri di gravità seguenti indicativi di asma instabile nei 7 giorni precedenti la randomizzazione.  Sintomi dell’asma persistenti per l’intera giornata in 2 giorni consecutivi.  Risvegli notturni dovuti all’asma ≥ 3 volte.  Uso di albuterolo/salbutamolo (o equivalente) per il peggioramento acuto dei sintomi dell’asma &gt; 8 puff al giorno per 2 giorni consecutivi o ≥ 25 puff in un giorno.  Gravità dei sintomi dell’asma tale da limitare la capacità del soggetto di svolgere le normali attività quotidiane in 1 giorno qualsiasi. 8. Esacerbazione dell’asma: un’esacerbazione dell’asma che necessita di corticosteroidi per via sistemica (compresse, sospensione o iniezione) nelle 4 settimane precedenti la randomizzazione oppure oltre 4 esacerbazioni distinte nei 12 mesi precedenti la randomizzazione. Affinché siano considerate eventi separati, tra la risoluzione di un’esacerbazione e l’inizio della successiva devono trascorrere almeno 7 giorni. 9. Ricoveri ospedalieri dovuti all’asma: oltre 2 Ricoveri ospedalieri (definite come ricovero o periodo di degenza presso Pronto soccorsoo altra struttura equivalente per osservazione)di durata superiore a 24 ore per il trattamento dell’asma nei 12 mesi precedenti la randomizzazione. Ciascuna ospedalizzazione deve avvenire a distanza di &gt; 7 giorni per essere considerata un evento a se stante.10. Gravidanza e allattamento: i soggetti di sesso femminile non possono essere arruolati se in stato di gravidanza, in allattamento o qualora pianifichino una gravidanza durante la partecipazione allo studio. Tutte le donne in età fertile (vedere Sezione 6.2.7 per la definizione) devono presentare risultato negativo a un test di gravidanza su urine precedente la randomizzazione per continuare a prendere parte allo studio. 11. Patologie/anomalie concomitanti: un soggetto con eventuali affezioni, patologie o disturbi preesistenti noti, clinicamente significativi, a carico di qualsiasi sistema organico, non controllati dalle terapie standard e che, nell’opinione dello Sperimentatore, metterebbero a rischio la sicurezza del soggetto durante la partecipazione allo studio o confonderebbero l’interpretazione dei risultati qualora peggiorassero nel corso dello studio. 12. Farmaci sperimentali: un soggetto che ha preso parte a uno studio interventistico o ha assunto eventuali farmaci sperimentali per qualsiasi malattia nei 30 giorni precedenti la randomizzazione.13. Partecipazione a uno studio concomitante sulla sicurezza dei LABA. - Per gli altri criteri di esclusione si faccia riferimento al protocollo.
    E.5 End points
    E.5.1Primary end point(s)
    The primary safety endpoint is the number of subjects experiencing an event in the composite endpoint of serious asthma outcomes (i.e., asthma-related hospitalization, asthma-related endotracheal intubation, or asthma-related death) over the 26-week study period. The primary efficacy endpoint is severe asthma exacerbations.
    L’endpoint di sicurezza primario è il numero di soggetti interessati da un evento dell’endpoint composito di esiti asma-correlati gravi (ovvero ospedalizzazione, intubazione endotracheale o morte per asma) durante il periodo di 26 settimane dello studio. L’endpoint di efficacia primaria è correlato alle gravi esacerbazioni dell’asma.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Within the 6 months post-randomization
    Entro 6 mesi dalla randomizzazione.
    E.5.2Secondary end point(s)
    Secondary safety endpoints include the individual component endpoints of asthmarelated hospitalization, endotracheal intubation, and death, and withdrawals from the study treatment due to asthma exacerbation. The secondary efficacy endpoints is albuterol/salbutamol use.
    Gli endpoint di sicurezza secondari includono gli endpoint di ospedalizzazione, intubazione endotracheale e morte per asma considerati singolarmente e i ritiri dal trattamento in studio dovuti a esacerbazioni dell’asma. L'endpoint di efficacia secondaria è l’uso di albuterolo/salbutamolo.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Entire treatment period (up to 6 months)
    Intero periodo di trattamento (fino a 6 mesi).
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic Yes
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other Yes
    E.8.1.7.1Other trial design description
    stratificato
    stratified
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) Yes
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial6
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned23
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA314
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    European Union
    Argentina
    Australia
    Brazil
    Canada
    Chile
    China
    Colombia
    Croatia
    Hong Kong
    India
    Indonesia
    Israel
    Japan
    Korea, Republic of
    Malaysia
    New Zealand
    Peru
    Russian Federation
    South Africa
    Taiwan
    Thailand
    Turkey
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last post-treatment follow up phone contact last subject
    Ultimo contatto telefonico di follow-up dell'ultimo paziente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years0
    E.8.9.1In the Member State concerned months53
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years0
    E.8.9.2In all countries concerned by the trial months56
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 1400
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 1400
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 9798
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 466
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2012-02-28. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others Yes
    F.3.3.7.1Details of other specific vulnerable populations
    Minors
    Minori
    F.4 Planned number of subjects to be included
    F.4.1In the member state700
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 2900
    F.4.2.2In the whole clinical trial 11664
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    No post-study medication will be provided. The investigator is responsible for ensuring that consideration has been given to the post-study care of the patient's medical condition.
    Non sarà fornita nessuna terapia farmacologica post-studio. Lo sperimentatore è responsabile di assicurare attenzione alle cure post-studio sulla base delle condizioni mediche del paziente.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2012-03-19
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2012-02-17
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2015-06-04
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 04:57:02 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA